Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Surgical oncology

Why biopsying metastatic breast cancer should be routine

Currently, acquisition of tissue from presumed metastatic deposits in breast cancer is not routine. Instead therapeutic decisions in this setting are based on the features of the tumor at initial diagnosis. As biopsies are diagnostic and changes can occur between the primary and the secondary tumors, the routine biopsy of suspected metastatic deposits needs to be considered. Such biopsies will also be key to translational research, which will underpin future therapeutic advances.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Kamangar, F., Dores, G. M. & Anderson, W. F. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 24, 2137–2150 (2006).

    Article  Google Scholar 

  2. 2

    Cardoso, F. et al. Clinical application of the 70-gene profile: the MINDACT trial. J. Clin. Oncol. 26, 729–735 (2008).

    Article  Google Scholar 

  3. 3

    Sparano, J. A. & Paik, S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J. Clin. Oncol. 26, 721–728 (2008).

    Article  Google Scholar 

  4. 4

    Simmons, C. et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann. Oncol. 20, 1499–1504 (2009).

    CAS  Article  Google Scholar 

  5. 5

    Li, B. D., Byskosh, A., Molteni, A. & Duda, R. B. Estrogen and progesterone receptor concordance between primary and recurrent breast cancer. J. Surg. Oncol. 57, 71–77 (1994).

    CAS  Article  Google Scholar 

  6. 6

    Wang, B. et al. Discordance of estrogen receptor (ER), progestin receptor (PR), and HER-2 receptor statuses between primary and metastatic focuses of breast cancer. Ai Zheng. 23, 1710–1713 (2004).

    CAS  PubMed  Google Scholar 

  7. 7

    Lipton, A. et al. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 104, 257–263 (2005).

    CAS  Article  Google Scholar 

  8. 8

    Kuukasjarvi, T., Kononen, J., Helin, H., Holli, K. & Isola, J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J. Clin. Oncol. 14, 2584–2589 (1996).

    CAS  Article  Google Scholar 

  9. 9

    Liedtke, C. et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann. Oncol. 20, 1953–1958 (2009).

    CAS  Article  Google Scholar 

  10. 10

    Weigelt, B. et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res. 65, 9155–9158 (2005).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Carlo Palmieri.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sharma, A., Crook, T., Thompson, A. et al. Why biopsying metastatic breast cancer should be routine. Nat Rev Clin Oncol 7, 72–74 (2010). https://doi.org/10.1038/nrclinonc.2009.222

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing